Earlier Use of Long-Acting Injectable Paliperidone Palmitate Once-Monthly versus Oral Antipsychotics in Patients with Schizophrenia: An Integrated Patient-Level Meta Analysis of the PROSIPAL and PRIDE Studies [Corrigendum]

Sajatovic M, Doring M, Lopena OJ, et al. Neuropsychiatr Dis Treat. 2024;20:2227—2235.

The authors have advised that there is a data error in Table 2 on page 2233. Under 0-3 Years n = 516, PP1M n = 253 column, Injection site pain row, the data “2 (9.5%)” should read “24 (9.5%)”. The correct Table 2 is as follows.

Table 2 Incidence of Treatment-Emergent Adverse Events

The authors apologize for this oversight.

Read the original article

© 2025 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, 4.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.